BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Monday. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.02, Bloomberg Earnings reports. BioCryst Pharmaceuticals had a negative return on equity of 320.73% and a negative net margin of 160.97%. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The firm’s quarterly revenue was down 35.4% on a year-over-year basis.

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 4.49 on Wednesday. The firm’s market capitalization is $361.09 million. The company has a 50-day moving average price of $5.56 and a 200-day moving average price of $6.34. BioCryst Pharmaceuticals has a one year low of $3.75 and a one year high of $9.25.

A number of analysts recently weighed in on the stock. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Tuesday, April 18th. Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. Finally, BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $8.29.

A number of large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares in the last quarter. Legal & General Group Plc increased its stake in BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 860 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,500 shares in the last quarter. Comerica Bank increased its stake in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 2,552 shares in the last quarter. Finally, American International Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 45,230 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,989 shares in the last quarter. Institutional investors own 84.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/biocryst-pharmaceuticals-inc-bcrx-posts-earnings-results-misses-expectations-by-0-02-eps.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.